Paricalcitol
- Generic Name
- Paricalcitol
- Brand Names
- Zemplar
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O3
- CAS Number
- 131918-61-1
- Unique Ingredient Identifier
- 6702D36OG5
Overview
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Background
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Indication
For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Associated Conditions
- Secondary Hyperparathyroidism (SHPT)
Clinical Trials
FDA Approved Products
Paricalcitol
Manufacturer:Aurobindo Pharma Limited
Route:ORAL
Strength:2 ug in 1 1
Approved: 2023/12/06
NDC:65862-937
Paricalcitol
Manufacturer:Dr. Reddy's Laboratories Limited
Route:ORAL
Strength:2 ug in 1 1
Approved: 2017/04/27
NDC:55111-664
Paricalcitol
Manufacturer:Dr. Reddy's Laboratories Limited
Route:ORAL
Strength:4 ug in 1 1
Approved: 2017/04/27
NDC:55111-665
PARICALCITOL
Manufacturer:Eugia US LLC
Route:INTRAVENOUS
Strength:10 ug in 2 mL
Approved: 2023/11/09
NDC:55150-215
Zemplar
Manufacturer:AbbVie Inc.
Route:INTRAVENOUS
Strength:5 ug in 1 mL
Approved: 2022/11/22
NDC:0074-1658
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath